.jpg)
2 hours ago
3
Article content
WHO-origin Master and Working Cell Banks provide vaccine developers with a ready-to-use Vero cell substrate for licensing, purchase, and integrated CDMO programs
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
- Qualified Vero Master Cell Bank and Working Cell Bank, originating from WHO banks, are available for purchase, licensing, and use in Intravacc-led CDMO programs
- Intravacc has used its Vero cell line for viral vaccine development since 1987, supporting oncolytic, live-attenuated, inactivated, and vector vaccine programs
- Integrated process development, analytics, cGMP manufacturing, quality control, and technology transfer help partners reduce CMC risk and move viral vaccine candidates toward clinical studies
Article content
Article content
Article content
BILTHOVEN, The Netherlands, June 30, 2026 (GLOBE NEWSWIRE) — Intravacc, a leading global contract development and manufacturing organization (CDMO) specializing in vaccine and biologics development and manufacturing, today highlighted the commercial availability of its qualified Vero Master Cell Bank (MCB) and Working Cell Bank (WCB), originating from WHO banks. The cell banks are available for purchase or licensing by qualified partners and can also serve as the starting point for Intravacc-led CDMO programs, including cell bank access, virus seed lot generation, process development, analytical development, cGMP manufacturing, and technology transfer.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
For developers of viral vaccines and viral vectors, access to a proven, well-characterized cell substrate can be a critical path decision. Intravacc’s cGMP-grade, regulatory-approved Vero cell line is the backbone of its cell-based viral vaccine production platform and has been used by Intravacc and its predecessors since 1987. The platform can support a wide range of viral vaccine approaches, including oncolytic, live-attenuated, inactivated, and vector vaccines for infectious disease and oncology applications.
Article content
Article content
Ivo Lemmens, Intravacc’s Managing Director, says:
Article content
“Speed, quality, and regulatory confidence matter from the first development decision. By making our Vero Master and Working Cell Banks available for licensing, purchase, and CDMO use, we are giving vaccine developers access to a ready-to-use cell substrate backed by decades of viral vaccine experience, established process know-how, and integrated GMP capabilities. Our goal is to help partners shorten timelines, reduce CMC uncertainty, and move high-value viral vaccine programs toward clinical evaluation more efficiently.”
Article content
Intravacc’s Vero cell platform is designed to help partners move quickly from feasibility to GMP readiness. The offering includes qualified MCB and WCB materials with supporting documentation, defined upstream and downstream process know-how, and optional technology transfer packages. The platform has been established at laboratory and pilot scales, is scalable for larger-volume production using microcarrier-based bioreactor processes, and can be supported by downstream processing to help ensure product purity.
English (US)